An Open Study Assessing the Safety and Tolerability of U3-1784

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Advanced Solid TumorsHepatocellular Cancer (HCC)
Interventions
DRUG

U3-1784

Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated

Trial Locations (4)

G12 0YN

Glasgow

Unknown

The Royal Marsden Hospital, Sutton

Guy's Hospital, London

The Christie NHS Foundation Trust, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY